Products
Products
Our therapeutic areas are diabetes, oncology and rare diseases
Mixtard 30 - Penfill Cartridges
Mixtard is a suspension for injection that contains the active substance human insulin.It is available as cartridges (Penfill). Mixtard contains both fast-acting (soluble) and long-acting (isophane) insulin: Mixtard 30: soluble insulin 30% and isophane insulin 70%
Flexpen - Insulin Pens
Levemir is a solution for injection that contains the active substance insulin detemir. It is available in pre-filled pens. NovoMix medicines contain the active substance insulin aspart (100 units/ml) combined with protamine to make it longer acting. It is available as: NovoMix 30 (30% insulin aspart and 70% insulin aspart protamine). NovoRapid is used to treat adults, adolescents and children over one year old who have diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.
Flexpen - Liraglutide (GLP-1) pens
Victoza is a medicine used in addition to diet and exercise in adults who have type 2 diabetes.It is used as an ‘add-on’ to other diabetes medicines. Victoza contains the active substance liraglutide.
NovoSeven - Haemophilia Products
NovoSeven is a medicine used to treat and to prevent bleeding after surgical procedures. It is used in patients with the following conditions: congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors’ (antibodies) against factor VIII or IX; acquired haemophilia (a bleeding disease caused by the development of inhibitors to factor VIII); congenital factor VII deficiency; Glanzmann’s thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot). NovoSeven contains the active substance eptacog alfa.
Hyrimoz - Biosimilar Adalimumab
Adalimumab, the active ingredient in Hyrimoz, is an inhibitor of tumor necrosis factor (TNF), a protein that is overproduced in certain autoimmune conditions—including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis—causing inflammation and tissue destruction in joints, mucosa or skin. Hyrimoz targets and blocks the protein that contributes to disease symptoms.
Rixathon -Biosimilar Rituximab
Rixathon is approved for non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis
